Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoid Malignancies: early-phase trial registry
2 of 3 indexed Lymphoid Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Lymphoid Malignancies: 3 US clinical trials tracked, 2 recruiting.
Lymphoid Malignancies is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Jennifer Amengual, running 1 of these trials.
Enrollment posture brief
Registry condition lymphoid-malignancies
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Lymphoid Malignancies lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoid Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoid Malignancies is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
AVM Biotechnology
NCT04329728
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
NCT06047886
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01947140
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoid Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoid Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoid Malignancies page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Lymphoid Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jennifer Amengual sponsors the most Lymphoid Malignancies trials on record, review their full trial history before evaluating a specific study. See Jennifer Amengual's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoid Malignancies condition card totals 3 registered trials; most-linked intervention Romidepsin; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.